CLINICAL TRIALS PROFILE FOR EPOETIN ALFA
✉ Email this page to a colleague
Biosimilar Clinical Trials for epoetin alfa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01121237 ↗ | MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5 | Completed | Hexal AG | 2010-02-01 | MONITOR-CKD5 is an observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the treatment of renal anaemia with biosimilar epoetin alfa in Stage 5 CKD patients requiring haemodialysis. | |
| NCT01121237 ↗ | MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5 | Completed | Sandoz | 2010-02-01 | MONITOR-CKD5 is an observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the treatment of renal anaemia with biosimilar epoetin alfa in Stage 5 CKD patients requiring haemodialysis. | |
| NCT02140736 ↗ | Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology | Completed | Hospira, Inc. | 2009-09-01 | The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for epoetin alfa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003681 ↗ | Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome | Unknown status | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | 1998-08-01 | RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. Epoetin alfa may stimulate red blood cell production and be an effective treatment for anemia in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine with or without epoetin alfa in treating patients who have myelodysplastic syndrome. |
| NCT00004917 ↗ | Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 2000-06-01 | RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may stimulate red blood cell production and treat anemia in patients with head and neck cancer. It is not yet known whether receiving radiation therapy with epoetin alfa is more effective than radiation therapy alone in treating anemic patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without epoetin alfa in treating anemic patients who have head and neck cancer. |
| NCT00004917 ↗ | Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer | Completed | Radiation Therapy Oncology Group | Phase 3 | 2000-06-01 | RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may stimulate red blood cell production and treat anemia in patients with head and neck cancer. It is not yet known whether receiving radiation therapy with epoetin alfa is more effective than radiation therapy alone in treating anemic patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without epoetin alfa in treating anemic patients who have head and neck cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for epoetin alfa
Condition Name
Clinical Trial Locations for epoetin alfa
Trials by Country
Clinical Trial Progress for epoetin alfa
Clinical Trial Phase
Clinical Trial Sponsors for epoetin alfa
Sponsor Name
